Positions for Horizon Pharma Inc (NASDAQ:HZNP)
In Q3 2018 Horizon Pharma Inc (NASDAQ:HZNP) big money sentiment decreased to 0.86, according to SEC filings. That’s down -0.36, from 2018Q2’s 1.22. 86 hedge funds opened new or increased positions, while 100 trimmed and sold stock positions in Horizon Pharma Inc so the sentiment dived. These funds own 134.96 million shares, that’s up from 130.42 million shares in 2018Q2. Funds holding Horizon Pharma Inc in top 10 changed to 3 from 4 for a decrease of 1. In total 25 funds closed positions, 75 reduced and 45 increased. Also 41 funds bought new Horizon Pharma Inc stakes.
Significant Horizon Pharma Inc Investors
As of Q3 2018 Venbio Select Advisor Llc has 4.01% invested in Horizon Pharma Inc. Horizon Pharma Inc’s shareholder Jabodon Pt Co owns 121,158 shares as of Q3 2018. Furthermore, Jw Asset Management Llc reported 270,775 shares in Horizon Pharma Inc equivalent to 2.86% of its US long stock exposure. The Sweden-based fund Rhenman & Partners Asset Management Ab have invested about 1.8% of the active investment manager’s stock portfolio in Horizon Pharma Inc. The Wisconsin-based fund 1492 Capital Management Llc holds 139,313 shares or 1.78% of their US long stock exposure.
Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally.The firm is worth $3.69 billion. The companyÂ’s marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout.Last it reported negative earnings. The Company’s products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
HZNP is hitting $22.01 during the last trading session, after increased 2.42%.Horizon Pharma Public Limited Company has volume of 1.08 million shares. Since February 2, 2018 HZNP has risen 34.43% and is uptrending. The stock outperformed the S&P500 by 34.43%.
On February, 27 Horizon Pharma Public Limited Company (NASDAQ:HZNP)’s earnings report is expected by WallStreet, Faxor reports. Analysts predict $0.54 earnings per share. That’s $0.25 up or 86.21 % from 2018’s earnings of $0.29. This could hit $90.51M profit for HZNP assuming the current $0.54 earnings per share will become reality. Wall Street forecasts -16.92 % negative EPS growth as of February, 27.
1492 Limited Liability, Wisconsin-based fund reported 139,313 shs. First Hawaiian State Bank accumulated 17,970 shs or 0.02% of the stock. State Of Wisconsin Inv Board invested in 168,400 shs or 0.01% of the stock. Quantitative Mgmt Ltd Llc owns 41,600 shs. Strs Ohio has invested 0% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Bluemountain Mgmt Ltd Limited Liability Company, a New York-based fund reported 23,204 shs. Hillsdale Incorporated reported 82,800 shs. Product Limited holds 0.13% in Horizon Pharma Public Limited Company (NASDAQ:HZNP) or 162,700 shs. Georgia-based Signaturefd Limited Liability Corp has invested 0% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Venbio Select Advisor Limited Liability reported 4.01% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Investment holds 0.03% of its capital in Horizon Pharma Public Limited Company (NASDAQ:HZNP) for 154,000 shs. Morgan Stanley invested in 0.01% or 1.18M shs. Balasa Dinverno And Foltz Lc reported 13,000 shs. Credit Suisse Ag holds 0% of its capital in Horizon Pharma Public Limited Company (NASDAQ:HZNP) for 190,375 shs. Spark Inv Mgmt Lc holds 0.34% or 303,000 shs in its capital.
Horizon Pharma Public Limited Company had 2 selling transactions and 0 insider purchases since August 16, 2018. This’s net activity of $9.00 million. CURTIS GEOFFREY M. also sold $204,361 worth of Horizon Pharma Public Limited Company (NASDAQ:HZNP) shs.
Horizon Pharma Public Limited Company (NASDAQ:HZNP) Ratings Coverage
Total analysts of 4 have positions in Horizon Pharma (NASDAQ:HZNP) as follows: 1 rated it a “Buy”, 0 with “Sell” and 3 with “Hold”. The positive are 25%. Since August 6, 2018 according to StockzIntelligence Inc Horizon Pharma has 4 analyst reports. On Friday, August 17 the stock of Horizon Pharma Public Limited Company (NASDAQ:HZNP) has “Equal-Weight” rating given by Morgan Stanley. On Thursday, November 15 the rating was downgraded by Mizuho to “Neutral”. On Monday, August 6 the rating was downgraded by BMO Capital Markets to “Market Perform”. On Thursday, August 9 the firm has “Buy” rating by Jefferies given.
For more Horizon Pharma Public Limited Company (NASDAQ:HZNP) news released briefly go to: Seekingalpha.com, Businesswire.com, Streetinsider.com, Seekingalpha.com or Benzinga.com. The titles are as follows: “Goldman confident with sales forecast for Horizon Pharma’s gout drug Krystexxa despite potential threat from Selecta Bio’s SEL-212 – Seeking Alpha” released on August 23, 2018, “Horizon Pharma plc and HemoShear Therapeutics Enter into Exclusive Drug Discovery Collaboration in Gout – Business Wire” on January 03, 2019, “Horizon Pharma (HZNP) Announces FDA Approval to Expand Age Range for RAVICTI Oral Liquid to Include Newborns – StreetInsider.com” with a publish date: December 27, 2018, “Horizon Pharma settles Ravicti patent dispute with Par Pharma – Seeking Alpha” and the last “Earnings Scheduled For November 7, 2018 – Benzinga” with publication date: November 07, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.